Biogen reports $2.8B revenue for Q3 2026

Quarterly report, 3 new risk factors

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

What changed since last quarter

3 new risk factors · 7 removed · 4 new legal mentions

Compared with the 10-Q for the period ended Jun 30, 2026.

New risk factors (3)

Cybersecurity threats and incidents also include supply chain attacks, which could cause a delay in the manufacturing of products including products produced for contract manufacturing or lead to a data privacy or security breach. Our key business partners face similar risks and any security breach of their systems…
As with many developing technologies, AI technologies, including generative AI and AI agents that can take actions on a user's behalf, present risks and challenges. For example, algorithms may be flawed, data sets may be insufficient, of poor quality or contain biased information; outputs may be inaccurate… +2 more paragraphs
Our international operations are also subject to regulation under U.S. law. For example, following Section 232 investigations, the U.S. federal government issued a Proclamation in April 2026 imposing a 100% tariff on imports of patented pharmaceuticals, biologics and associated ingredients, subject to certain…

Removed risk factors (7)

While we believe we have a number of promising programs in our pipeline, failure or delay of internal development projects to advance or difficulties in executing on our commercial initiatives could impact our current and future growth, resulting in additional reliance on external development opportunities for growth.
We have made, and may continue to make, significant operating and capital expenditures for potential new products prior to regulatory approval with no assurance that such investment will be recouped, which may adversely affect our financial condition, business and operations.
Regulations continue to change as regulators worldwide consider new rules. For example, the SEC has adopted additional disclosure rules regarding cyber security risk management, strategy, governance and incident reporting by public companies. These regulations or other regulations being considered in Europe and…
As with many developing technologies, AI-based software presents risks and challenges. For example, algorithms may be flawed, data sets may be insufficient, of poor quality or contain biased information; and inappropriate or controversial data practices could impair results. AI-based software is increasingly used in…
delays in clinical trials relating to geopolitical instability related to Russia's invasion of Ukraine and the military conflict in the Middle East;
and 2 more in the filing

New legal mentions (4)

In August 2026 the U.S. Court of Appeals for the First Circuit affirmed dismissal of the action brought by Michigan Laborers' Pension Fund and Ray Peleckas.. +2 more paragraphs
In July 2026, Fresenius Kabi filed a claim for damages and injunctive relief against Biogen Inc., Biogen MA Inc., Biogen Netherlands B.V., Biogen Italia S.r.l., and Samsung Bioepis NL B.V. in the Court of Milan, Commercial Division, in Italy alleging infringement of the Italian counterpart of the EP '488 Patent by a… +3 more paragraphs
All of these parties have counterclaimed for damages based on our actions to enforce TECFIDERA's regulatory marketing protection.
The cases against Somerset and Cipla have been consolidated, and trial is scheduled for May 2028.

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.